In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cormorant Pharmaceuticals AB

Division of Bristol-Myers Squibb Co.
cormorantpharma.com

Latest From Cormorant Pharmaceuticals AB

Biopharma Quarterly Dealmaking Statistics, Q3 2016

In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.

BioPharmaceutical Deals

Deals Shaping the Medical Industry, August 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2016.

Market Intelligence Deals

Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks

With Opdivo sales up to $840m in the second quarter, Bristol execs once again make the case for trial strategy in the all-important first-line lung cancer indication and say they look forward to the CheckMate 026 data “in weeks not months.”

Cancer Research & Development

Deal Watch: Medivation Enters Confidential Talks With Suitors, Including Sanofi

Bristol acquires Swedish biotech Cormorant to bolster its immuno-oncology franchise. Moderna quickly follows up its cancer partnership with another with Vertex to use mRNA approaches to treat cystic fibrosis.

Deals Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Bristol-Myers Squibb Co.
  • Senior Management
  • Maarten de Chateau, MD, PhD, CEO
  • Contact Info
  • Cormorant Pharmaceuticals AB
    ,
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register